cabergoline has been researched along with Disease, Pulmonary in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gorgulu, C; Ozkurt, H; Tufaner, O | 1 |
| Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM | 1 |
| Gayete, A; Grau, S; Orozco-Levi, M; RamÃrez-Sarmiento, A; Villavicencio, C | 1 |
| Ahlskog, JE; Limper, AH; Ling, LH; Munger, TM; Oh, JK | 1 |
| Demedts, M; Dom, R; Frans, E | 1 |
| Bhatt, MH; Calne, DB; Fleetham, JA; Keenan, SP | 1 |
6 other study(ies) available for cabergoline and Disease, Pulmonary
| Article | Year |
|---|---|
[Pulmonary toxicity associated with cabergoline].
Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Female; Humans; Lung Diseases | 2009 |
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Topics: Acromegaly; Blood Sedimentation; C-Reactive Protein; Cabergoline; Creatinine; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Electrocardiography; Ergolines; Female; Fibrosis; Glomerular Filtration Rate; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Lung; Lung Diseases; Male; Middle Aged; Respiratory Function Tests; Retroperitoneal Fibrosis; Statistics, Nonparametric | 2010 |
[Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Humans; Lung Diseases; Male; Pleural Effusion; Time Factors | 2007 |
Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Lung Diseases; Male; Parkinson Disease, Secondary; Pericarditis, Constrictive; Pleural Diseases; Tomography, X-Ray Computed | 1999 |
Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
Topics: Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Humans; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion | 1992 |
Pleuropulmonary disease associated with dopamine agonist therapy.
Topics: Aged; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Lisuride; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Diseases; Radiography | 1991 |